Avalo Therapeutics (AVTX) Debt Ratio (2014 - 2023)

Avalo Therapeutics' Debt Ratio history runs 9 years deep, the most recent figure standing at 0.29 for Q1 2023.

• Quarterly Debt Ratio fell 46.1% year-over-year to 0.29 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was 0.29 (down 46.1% YoY) and the FY2022 annual result came in at 0.4, down 1.26% from the prior year.
• Debt Ratio was 0.29 for Q1 2023 at Avalo Therapeutics, down from 0.4 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.58 in Q2 2022 and bottomed at 0.22 in Q1 2019.
• A 4-year average of 0.37 and a median of 0.34 in 2021 frame the typical range for Debt Ratio.
• Annual changes were most pronounced in 2022 — Debt Ratio soared 117.09% — and 2023, when it slumped 46.1%.
• Avalo Therapeutics' Debt Ratio stood at 0.27 in 2019, then surged by 51.11% to 0.41 in 2021, then fell by 1.26% to 0.4 in 2022, then dropped by 28.51% to 0.29 in 2023.
• Business Quant data shows AVTX's Debt Ratio at 0.29 in Q1 2023, 0.4 in Q4 2022, and 0.45 in Q3 2022.